Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “DSM-5 Schizophrenia”

12 trials

Showing 12 of 12 results

Large-scale testing (Phase 3)Study completedNCT04659174
What this trial is testing

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Who this might be right for
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 152
Large-scale testing (Phase 3)Study completedNCT05919823
What this trial is testing

Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

Who this might be right for
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 202
Large-scale testing (Phase 3)Looking for participantsNCT06882785
What this trial is testing

Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

Who this might be right for
Schizophrenia
Bristol-Myers Squibb 250
Large-scale testing (Phase 3)Study completedNCT04820309
What this trial is testing

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Who this might be right for
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 566
Post-approval studies (Phase 4)Not Yet RecruitingNCT06924255
What this trial is testing

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

Who this might be right for
Schizophrenia Disorders
Collaborative Neuroscience Research, LLC 100
Large-scale testing (Phase 3)Ended earlyNCT05643170
What this trial is testing

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

Who this might be right for
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 4
Testing effectiveness (Phase 2)Looking for participantsNCT07467993
What this trial is testing

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

Who this might be right for
Schizophrenia
Novartis Pharmaceuticals 142
Not applicableEnded earlyNCT03471013
What this trial is testing

Impact of Caregiver Beliefs on Adherence to Antipsychotic Medications in Patients With Schizophrenia

Who this might be right for
DSM-5 Schizophrenia
University Hospital, Clermont-Ferrand 50
Large-scale testing (Phase 3)Study completedNCT04738123
What this trial is testing

Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

Who this might be right for
SchizophreniaSchizophrenia; Psychosis
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 256
Testing effectiveness (Phase 2)Study completedNCT03697252
What this trial is testing

Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

Who this might be right for
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 182
Large-scale testing (Phase 3)Study completedNCT04659161
What this trial is testing

Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

Who this might be right for
SchizophreniaSchizophrenia; Psychosis
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 252
Large-scale testing (Phase 3)Study completedNCT06572449
What this trial is testing

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

Who this might be right for
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 173

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation